CN114174341A - 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 - Google Patents

抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 Download PDF

Info

Publication number
CN114174341A
CN114174341A CN202080054708.9A CN202080054708A CN114174341A CN 114174341 A CN114174341 A CN 114174341A CN 202080054708 A CN202080054708 A CN 202080054708A CN 114174341 A CN114174341 A CN 114174341A
Authority
CN
China
Prior art keywords
seq
sequence
antibody
antigen
spik
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080054708.9A
Other languages
English (en)
Chinese (zh)
Inventor
陆选永
F·陆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingkai Biotechnology Co ltd
Original Assignee
Yingkai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingkai Biotechnology Co ltd filed Critical Yingkai Biotechnology Co ltd
Priority to CN202510175468.2A priority Critical patent/CN119874926A/zh
Publication of CN114174341A publication Critical patent/CN114174341A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080054708.9A 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 Pending CN114174341A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510175468.2A CN119874926A (zh) 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871565P 2019-07-08 2019-07-08
US62/871,565 2019-07-08
PCT/US2020/041228 WO2021007338A1 (en) 2019-07-08 2020-07-08 Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510175468.2A Division CN119874926A (zh) 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法

Publications (1)

Publication Number Publication Date
CN114174341A true CN114174341A (zh) 2022-03-11

Family

ID=71944318

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080054708.9A Pending CN114174341A (zh) 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法
CN202510175468.2A Pending CN119874926A (zh) 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510175468.2A Pending CN119874926A (zh) 2019-07-08 2020-07-08 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法

Country Status (6)

Country Link
US (1) US12377162B2 (https=)
EP (1) EP3996816A1 (https=)
JP (2) JP7658946B2 (https=)
CN (2) CN114174341A (https=)
CA (1) CA3145301A1 (https=)
WO (1) WO2021007338A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901699A (zh) * 2019-09-11 2022-08-12 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
US20250369960A1 (en) * 2022-06-30 2025-12-04 Allonnia, Llc Per- and polyfluorinated alkyl compound (pfas) binding proteins and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369218A (zh) * 2009-04-01 2012-03-07 霍夫曼-拉罗奇有限公司 抗-FcRH5抗体和免疫缀合物以及应用方法
WO2012078752A2 (en) * 2010-12-09 2012-06-14 Philadelphia Health & Education Corporation D/B/A Serine protease inhibitor kazal antibodies
CN104994875A (zh) * 2013-02-15 2015-10-21 免疫医疗公司 嵌合和人源化抗组蛋白抗体
CN109678950A (zh) * 2019-01-08 2019-04-26 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2007030560A2 (en) 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CA2703140A1 (en) 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
US20110206697A1 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021050217A1 (en) * 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369218A (zh) * 2009-04-01 2012-03-07 霍夫曼-拉罗奇有限公司 抗-FcRH5抗体和免疫缀合物以及应用方法
WO2012078752A2 (en) * 2010-12-09 2012-06-14 Philadelphia Health & Education Corporation D/B/A Serine protease inhibitor kazal antibodies
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
CN104994875A (zh) * 2013-02-15 2015-10-21 免疫医疗公司 嵌合和人源化抗组蛋白抗体
CN109678950A (zh) * 2019-01-08 2019-04-26 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901699A (zh) * 2019-09-11 2022-08-12 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位

Also Published As

Publication number Publication date
JP2022540079A (ja) 2022-09-14
WO2021007338A1 (en) 2021-01-14
JP2025111457A (ja) 2025-07-30
US12377162B2 (en) 2025-08-05
CA3145301A1 (en) 2021-01-14
CN119874926A (zh) 2025-04-25
JP7658946B2 (ja) 2025-04-08
EP3996816A1 (en) 2022-05-18
US20220273810A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
RU2488593C2 (ru) Человеческое опухолеспецифическое моноклональное антитело
JP6233933B2 (ja) 葉酸リセプターα及びβを認識する抗体
JP7658946B2 (ja) カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7539536B2 (ja) セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法
CN115998901B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN114206941A (zh) 抗her2/抗4-1bb双特异性抗体及其用途
EP3543259A2 (en) Antibody binding to carbonic anhydrase and use thereof
JP2026012693A (ja) 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
CN105452297A (zh) mAb 2抗-Met抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US9840560B2 (en) Monoclonal antibodies to EGFR, and uses therefor
KR20260016944A (ko) 항-클라우딘18.2 항체 및 이의 제조 및 사용 방법
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
CN113194992A (zh) 靶向epn1的抗体
HK40058922A (en) Antibodies targeting epn1
BR112019019505B1 (pt) Anticorpo anti-dr5 e a utilização do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination